Sponsor hub
Swiss Cancer Institute clinical trial failures
Review 26 stopped clinical trials from Swiss Cancer Institute, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 0 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 14
- OTHER/UNKNOWN
- 12
Notable sponsors
- Swiss Cancer Institute
- 26
Related phases
- Phase II
- 13
- Phase I
- 8
- Phase III
- 5
Crawlable stopped-trial records
Open ExploreShowing up to 26 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II Relapsed/Refractory Chronic Lymphocytic Leukemia trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.
Phase III Colon Cancer trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Board decision in 2020 due to lack of financial funding.
Phase II Seminoma trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Board decided to prematurely terminate the follow-up phase of the trial due to funding reasons
Phase I Advanced Solid Tumors trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part.
Phase I Metastatic Castration-resistant Prostate Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
SAKK decided to premature terminate this trial as additional follow-up visits do not further contribute to the efficacy data. This decision does not adversely impact the patients.
Phase II Prostate Cancer Metastatic trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Decision Board no further financial support after 3 years of follow-up as remaining patients in follow-up phase would not relevantly change the endpoints.
Phase II Follicular Lymphoma trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
The premature termination is based on the decision by the SAKK board on November 14, 2020 due to the lack of further financial support for the follow up period.
Phase II Metastatic Breast Adenocarcinoma trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
The SAKK board decided to prematurely end the life-long follow-up of the trial SAKK 21/12, as 90% of the patients have died.
Phase II Cancer of the Prostate trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
The decision is based on the fact that with the current follow up of around 10 years, the relevant secondary endpoints can adequately be addressed according to protocol. The addition of follow up data will not significantly impact these results.
Phase II Lymphoma trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
It was decided by the trial team to stop the collection of follow up data in trial SAKK 35/10.
Phase III Breast Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.
Phase I Rectal Cancer trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
due to structural financial deficit of SAKK
Phase II Squamous-cell Non-small Cell Lung Cancer trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Due to financial restructure of SAKK
Phase I Soft Tissue Sarcoma trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
As Last patient last visit (LPLV) took place on 15/02/2022, the trial was ended prematurely on this date in accordance with SAKK/CI.
Phase I Multiple Myeloma trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated.
Phase II Prostate Cancer trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened to one year after last RT fraction of the last patient
Phase I Non-Hodgkin Lymphoma trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Insufficient Funding
Phase I Mantle Cell Lymphoma trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
SAKK Board decision of 14th November 2020 due to financial reasons.
Phase II Breast Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The trial is to be terminated after primary endpoint is reached.
Phase II Breast Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
The trial was prematurely terminated as of 22.07.2021 as per SAKK board decision board decision from 14th of November 2020. The trial was terminated after the primary endpoint was analyzed, which was the case end of December 2020.
Phase III Breast Cancer trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Feasibility (low patient accrual and financial reasons)
Phase II Refractory Multiple Myeloma trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
Feasibility (low patient accrual and financial reasons)
Phase III Colorectal Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.
Phase III Prostate Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
Due to former trials, drug has not demonstrated a clinical profile sufficient to move forward in mCRPC
Phase II Metastatic Colorectal Cancer trial by Swiss Cancer Institute. Stop reason: OTHER/UNKNOWN.
FU for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of FU.
Phase I Liver Cancer trial by Swiss Cancer Institute. Stop reason: OPERATIONAL.
due to slow patient recruitement.